Targeted Cancer Therapies
Binimetinib
BPT-1203 · Tablet
What is it used for?
Blocks MEK signaling involved in cancer-cell growth. Used with encorafenib for BRAF V600E/V600K unresectable or metastatic melanoma, and BRAF V600E metastatic non-small-cell lung cancer. The V600K lung-cancer claim in the supplier sheet should not be treated as an approved indication.
- Dosage form
- Tablet
- Listed strengths
- 15 mg
- Listed pack size
- 90's
- Mechanism
- MEK inhibitor
Specifications supplied in the Everest product list; formulation, pack configuration, availability and local authorization require confirmation. These medicines are not for self-medication.
Clinical use overview
- BRAF V600E/V600K melanoma, with encorafenib
- BRAF V600E metastatic non-small-cell lung cancer, with encorafenib
Important information
Educational information about the active ingredient, not a treatment recommendation or a claim that Beptide's presentation is approved. Approved uses differ by country and product. Cancer medicines require specialist assessment; biomarkers, stage, previous treatments and combinations can determine eligibility.
FDA prescribing information
